Health News Releases

August 09, 2024 15:00

BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates

BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54105663&newsitemid=20240807337131&lan=en-US&anchor=BeiGene&index=1&md5=66784fdcb48f17570d0bd05940b

August 08, 2024 15:25

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54104396&newsitemid=20240806343138&lan=en-US&anchor=TSE%3A4

August 05, 2024 14:39

Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

Galderma today announced that it has signed a memorandum of understanding with L’Oréal to work towards a new research and development (R&D) collaboration in the form of a scientific partnership focuse

August 02, 2024 09:40

In-Depth Report on Global Oesophageal Cancer Clinical Trials Now Available

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, ha

August 01, 2024 15:30

Boston Oncology and King Fahd Medical City (KFMC) Partner to Advance Localized Cell & Gene Therapy in Saudi Arabia

In a landmark initiative poised to transform healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a Letter of Intent to collaborate on the localizat

August 01, 2024 14:30

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that it has entered into an o

August 01, 2024 14:00

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54099945&newsitemid=20240725145481&lan=en-US&anc

July 31, 2024 11:40

Carestream Wins Renowned Award for Dental Films

We’re excited to announce Carestream recently received the Health Leaders Award in the Dental Category from Grupo Mídia in Brazil, a renowned international multimedia company. This distinguished aw

July 31, 2024 10:45

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

Biogen Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.biogen.com&esheet=54101572&newsitemid=20240730216833&lan=en-US&anchor=Biogen+Inc.&index=1&md5=4c98be33119620eca3992544

July 30, 2024 15:15

Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test for colorectal cance

July 30, 2024 14:32

Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

Galderma today announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for Relfydess™ (RelabotulinumtoxinA - previously referred to as QM1114). Rel

July 30, 2024 11:45

Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience

Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=54098752&newsitemid=20240724837236&lan=en-US&anchor=Medidata&index=1&md5=67239cebded0696c115

July 28, 2024 10:50

Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay system

July 25, 2024 17:25

Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

Galderma Group AG, the pure-play dermatology category leader, today announced its financial results for the first half of 2024. · Record net sales of 2.2 billion USD in the first half of 2024, with

July 25, 2024 15:31

PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis - Itch, Skin Lesions and Sleep Disturbance

Galderma today announced that full results from the phase III ARCADIA 1 and 2 clinical trials in atopic dermatitis were published in The Lancet (https://cts.businesswire.com/ct/CT?id=smartlink&url=htt

July 25, 2024 14:30

Pearl Raises Largest-Ever Investment in Dental AI with $58 Million Round

Pearl (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhellopearl.com%2F%3Futm_campaign%3DPress%2520Releases%26utm_source%3Dlink&esheet=54098764&newsitemid=20240724200226&lan=en-US&a

July 25, 2024 10:00

Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced that it has extended and expanded its manufacturing c

July 24, 2024 13:45

BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the opening of its flagship U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus,

July 21, 2024 10:25

MicroVention Announces Settlement Against Former Employees for Trade Secret Misappropriation and Breach of Contract Among Other Claims

MicroVention, a fully owned subsidiary of Terumo Corporation, announced today that the United States District Court for the Central District of California has issued an injunction permanently enjoinin

July 19, 2024 15:10

BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer

BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54096137&newsitemid=20240718157915&lan=en-US&anchor=BeiGene&index=1&md5=7fb29a782461d2203a45fc454af

July 19, 2024 14:30

Hanyang University’s Digital Healthcare Center and MIT Media Lab Sign MOU to Jointly Develop Proposals for Research Collaborations

On July 8, Hanyang University’s Digital Healthcare Center signed a memorandum of understanding (MOU) with the Massachusetts Institute of Technology (MIT) Media Lab in Cambridge, Massachusetts, USA, to

July 19, 2024 10:30

Brandnew Lab to Host Symposium on New Clinic-Use Ampoule ‘Nuvoen’

Brandnew Lab will be holding a symposium on July 22nd at the Brandnew Clinic in Cheongdam to introduce its new line of clinic-use ampoules, ‘NUVOEN’. At the symposium, Dr. Yoon Song Eun, the direct

July 17, 2024 14:50

SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline

SOTIO Biotech (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.sotio.com%2F&esheet=54094919&newsitemid=20240716652691&lan=en-US&anchor=SOTIO+Biotech&index=1&md5=279e5245d8e335ff5

July 12, 2024 15:20

ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders’ Voices Expressed at the AGM

ILJIN SNT Co., Ltd. (“ILJIN”), one of the largest shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued an open letter to fellow shareholders. The full text

July 12, 2024 11:30

Parse Biosciences Launches Certified Service Provider Program

Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54093141&newsitemid=20240711445815&lan=en-US&anchor=Parse+Biosciences&index=1&md

News by Region

News by Industry